Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Pemvidutide

Pemvidutide

GLP-1/GCG · s.c. · Altimmune

Data cut 12 November 2026 · page built 16 November 2026 · 1 trial arms · 2 trials with results · 4 registered trials · see on the pipeline board

Summary

Also known as
ALT-801
Mechanism
GLP-1/GCG
Route
s.c.
Company
Altimmune
Highest development stage
phase 3
Status (as of data cut)
Phase 3 PERFORMA in MASH recruiting since Jul 2026; phase 2 MOMENTUM (obesity) and IMPACT (MASH) complete verify
Next milestone
PERFORMA results (primary completion Dec 2028)

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity1 phase 2 / signalPhase 2 (MOMENTUM)
T2D0 no data
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH2 phase 3 ongoingPhase 2b IMPACT: MASH resolution met, fibrosis improvement not met at 24 weeks (Lancet 2025); phase 3 PERFORMA recruitingPERFORMA; IMPACT 24 weeks, Lancet 2025; IMPACT 48 weeks, Lancet Gastroenterol Hepatol 2026
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
MOMENTUMpemvidutide 2.4 mgobesity48391——−15.6 % vs −2.2 %
estimand not specified
—19.6 vs 6.2—51.5 vs 11.327.8 vs 3.1—−4.6 vs +3.5press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (5)
  • pemvidutide 2.4 mg · ae_dc · Summary of Safety and Tolerability table: Placebo (N=97) | 1
    All AEs leading to discontinuation N (%) | 6 (6.2%) | 5 (5.1%) | 19 (19.2%) | 19 (19.6%)
  • pemvidutide 2.4 mg · nausea · Summary of Safety and Tolerability table: Placebo (N=97) | 1
    Nausea N (%) | 11 (11.3%) | 25 (25.5%) | 59 (59.6%) | 50 (51.5%)
  • pemvidutide 2.4 mg · vomiting · Summary of Safety and Tolerability table: Placebo (N=97) | 1
    Vomiting N (%) | 3 (3.1%) | 6 (6.1%) | 27 (27.3%) | 27 (27.8%)
  • pemvidutide 2.4 mg · sbp · Blood Pressure and Heart Rate table
    Blood Pressure and Heart Rate | Placebo (N=97) | 1.2 mg (N=98) | 1.8 mg (N=99) | 2.4 mg (N=97) Δ Systolic BP mm Hg, LSM (SE) | +3.5 (2.3) | -2.3 (2.2) | -1.6 (2.2) | -4.6 (2.3)
  • pemvidutide 2.4 mg · weight_unsp · Summary of Efficacy Findings
    Primary Endpoint: Body weight | Placebo (N=97) | 1.2 mg (N=98) | 1.8 mg (N=99) | 2.4 mg (N=97) Δ Body weight, all subjects, %, LSM (SE) [1 MMRM] | -2.2 (1.4) | -10.3 (1.4)*** | -11.2 (1.4)*** | -15.6 (1.4)***

Outcome trials

Other indications

IMPACT Pemvidutide · MASH F2–F3 · 24 weeks · n = 212 abstract

MASH resolution without worsening of fibrosis +38 / +32 percentage points vs placebo at 24 weeks (1.2 / 1.8 mg); fibrosis improvement +5 / +8, not significant. At 48 weeks (no biopsy): liver fat −37.1 / −46.5 percentage points vs placebo.

MeasureDrugControlDifference (95 % CI)Status
MASH resolution without worsening of fibrosis 1.2 mg
week 24
+58.0+20.0+38.0 (+21.0 to +56.0) percentage pointsabstract
MASH resolution without worsening of fibrosis 1.8 mg
week 24
+52.0+20.0+32.0 (+19.0 to +46.0) percentage pointsabstract
Fibrosis improvement (≥1 stage) without worsening of MASH 1.2 mg
week 24
+33.0+28.0+5.0 (−13.0 to +22.0) percentage pointsabstract
Fibrosis improvement (≥1 stage) without worsening of MASH 1.8 mg
week 24
+36.0+28.0+8.0 (−6.0 to +22.0) percentage pointsabstract
Verbatim quotes (4)
  • MASH resolution without worsening of fibrosis
    MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1.2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0.0001), and 45 (52%) of 85 patients in the 1.8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0.0001)
  • MASH resolution without worsening of fibrosis
    MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1.2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0.0001), and 45 (52%) of 85 patients in the 1.8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0.0001)
  • Fibrosis improvement (≥1 stage) without worsening of MASH
    Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1.2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0.59), and 30 (36%) of 85 patients in the 1.8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0.27)
  • Fibrosis improvement (≥1 stage) without worsening of MASH
    Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1.2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0.59), and 30 (36%) of 85 patients in the 1.8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0.27)

Registered trials (4)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
PERFORMA
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
MASHPhase 3recruiting2026-07 → 2028-121800recruitingNCT07795164
RESTORE TRIAL
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
OtherPhase 2active not recruiting2025-06 → 2027-09121active not recruitingNCT07009860
RECLAIM STUDY
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
AddictionPhase 2completed2025-05 → 2026-07100Completed; results not in the atlas yetNCT06987513
IMPACT
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
CV outcomesPhase 2completed2023-07 → 2025-11212Completed; results not yet publicNCT05989711

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Pemvidutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/pemvidutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.